Analysis of immune infiltrate identifies checkpoint blockade and TLR3 activation as efficient synergistic combination of immunotherapy in rhabdoid tumors

被引：2
|
作者：
Leruste, Amaury [1 ]
Han, Zhi-Yan [1 ]
Tauziede-Espariat, Arnault [2 ]
Caudana, Pamela [1 ]
Waterfall, Joshua J. [1 ]
Andrianteranagna, Mamy [1 ]
Sedlik, Christine [1 ]
Ramos, Rodrigo [1 ]
Viel, Sophie [1 ]
Chauvin, Celine [1 ]
Delattre, Olivier [1 ]
Piaggio, Eliane [1 ]
Bourdeaut, Franck [1 ]
机构：
[1] Paris Sci Lettres, Inst Curie Res Ctr, Paris, France
[2] St Anne Hosp, Paris, France
来源：
CANCER RESEARCH | 2018年 / 78卷 / 19期
关键词：
D O I：
10.1158/1538-7445.PEDCA17-PR03
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PR03
引用
收藏
页数：2
相关论文
共 21 条
  • [1] TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer
    Li, Yingying
    Jiang, Xiaomin
    Luo, Taokun
    Xia, Junjie
    Lee, Morten J.
    Weichselbaum, Ralph R.
    Lin, Wenbin
    BIOMATERIALS, 2022, 290
  • [2] SMARCB1-DEFICIENT TUMORS ACTIVATE BOTH INNATE AND ADAPTIVE IMMUNE RESPONSES AND ARE SUSCEPTIBLE TO CHECKPOINT BLOCKADE AND TLR3 ACTIVATION
    Leruste, Amaury
    Caudana, Pamela
    Tauziede-Espariat, Arnault
    Han, Zhi-Yan
    Ramos, Rodrigo N.
    Nikolic, Jovan
    Tosello, Jimena
    Brohard, Solene
    Andrianteranagna, Mamy
    Chauvin, Celine
    Masliah-Planchon, Julien
    Sedlick, Christine
    Coulomb, Aurore
    Galmiche-Rolland, Louise
    Ranchere, Dominique
    Benaroch, Philippe
    Waterfall, Joshua J.
    Delattre, Olivier
    Piaggio, Eliane
    Bourdeaut, Franck
    NEURO-ONCOLOGY, 2018, 20 : 35 - 35
  • [3] Reverse Translation Identifies the Synergistic Role of Immune Checkpoint Blockade and IL15 to Enhance Immunotherapy of Ovarian Cancer
    Felices, Martin
    Wesley, Erin
    Bendzick, Laura E.
    Kodal, Behiye
    Hopps, Rachel
    Grzywacz, Bartosz
    Hinderlie, Peter
    Miller, Jeffrey S.
    Geller, Melissa A.
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (05) : 674 - 686
  • [4] PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
    Koerner, Julia
    Horvath, Dennis
    Herrmann, Valerie L.
    MacKerracher, Anna
    Gander, Bruno
    Yagita, Hideo
    Rohayem, Jacques
    Groettrup, Marcus
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [5] PLGA-particle vaccine carrying TLR3/RIG-I ligand Riboxxim synergizes with immune checkpoint blockade for effective anti-cancer immunotherapy
    Julia Koerner
    Dennis Horvath
    Valerie L. Herrmann
    Anna MacKerracher
    Bruno Gander
    Hideo Yagita
    Jacques Rohayem
    Marcus Groettrup
    Nature Communications, 12
  • [6] Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
    Sweta Karan
    Eunkyeong Jung
    Christine Boone
    Nicole F. Steinmetz
    Cancer Immunology, Immunotherapy, 73
  • [7] Synergistic combination therapy using cowpea mosaic virus intratumoral immunotherapy and Lag-3 checkpoint blockade
    Karan, Sweta
    Jung, Eunkyeong
    Boone, Christine
    Steinmetz, Nicole F.
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (03)
  • [8] Local therapy with combination TLR agonists stimulates systemic anti-tumor immunity and sensitizes tumors to immune checkpoint blockade
    Rwandamuriye, Francois Xavier
    Wang, Tao
    Zhang, Hanfu
    Elaskalani, Omar
    Kuster, Jorren
    Ye, Xueting
    Vitali, Breana
    Schreurs, Juliet
    Morales, M. Lizeth Orozco
    Norret, Marck
    Evans, Cameron W.
    Zemek, Rachael M.
    Iyer, K. Swaminathan
    Lesterhuis, W. Joost
    Wylie, Ben
    ONCOIMMUNOLOGY, 2024, 13 (01):
  • [9] A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade
    Zhang, Xiaodian
    Tian, Hailong
    Chen, Yang
    Liang, Baichuan
    Nice, Edouard C.
    Huang, Canhua
    Xie, Na
    Zheng, Shaojiang
    JOURNAL OF NANOBIOTECHNOLOGY, 2024, 22 (01)
  • [10] Synergistic cancer immunotherapy combination of MVA-CD40L with tumor targeting antibodies or checkpoint blockade to achieve strong antitumor immune responses against large, established tumors
    Medina-Echeverz, Jose
    Hinterberger, Maria
    Giessel, Raphael
    Bathke, Barbara
    Kassub, Ronny
    Fiore, Giovanna
    Chaplin, Paul
    Hochrein, Hubertus
    Lauterbach, Henning
    CANCER RESEARCH, 2019, 79 (13)
123